A Phase 1/2 Study of AZD6244 in Combination With Sorafenib in Advanced Hepatocellular Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 28 Sep 2016
At a glance
- Drugs Selumetinib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- 28 Sep 2016 Results from phase Ib part of this study (n=27) published in the Annals of Oncology.
- 15 Apr 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov. record.
- 07 Nov 2012 Planned number of patients changed from 100 to 166 as reported by ClinicalTrials.gov.